Neurodazine |
| Catalog No.GC11454 |
Induces neurogenesis of non-pluripotent C2C12 myoblasts
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 937807-66-4
Sample solution is provided at 25 µL, 10mM.
GlpBio Products Cited In Reputable Papers
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Product Documents
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cas No. | 937807-66-4 | SDF | |
| Chemical Name | 2-(5-(3-chlorophenyl)furan-2-yl)-4,5-bis(4-methoxyphenyl)-1H-imidazole | ||
| Canonical SMILES | ClC1=CC(C2=CC=C(C3=NC(C(C=C4)=CC=C4OC)=C(C(C=C5)=CC=C5OC)N3)O2)=CC=C1 | ||
| Formula | C27H21ClN2O3 | M.Wt | 456.92 |
| Solubility | DMF: 20 mg/ml,DMSO: 20 mg/ml,Ethanol: 10 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
Complete Stock Solution Preparation Table
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1886 mL | 10.9428 mL | 21.8857 mL |
| 5 mM | 0.4377 mL | 2.1886 mL | 4.3771 mL |
| 10 mM | 0.2189 mL | 1.0943 mL | 2.1886 mL |
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Related Products
- GC10134 Ginkgolic Acid C15:1
- GC14955 Barasertib (AZD1152-HQPA)
- GC61594 Lu AE98134
- GC37013 PROTAC MDM2 Degrader-4
- GC34464 AM-4668
- GC33870 Veledimex racemate (RG-115932 racemate)
- GC36532 Maleic Acid
- GC18080 GR 73632
- GC32166 NITD-349
- GC36011 Ethylenediaminetetraacetic acid trisodium salt
- GC45552 Pyrenophorol
- GC31386 (-)-PX20606 trans isomer ((-)-PX-102 trans isomer)
- GC30980 Pardoprunox hydrochloride (SLV-308 hydrochloride)
- GC40164 Ac-IETD-CHO (trifluoroacetate salt)
- GC34162 KRAS G12C inhibitor 5
- GC35641 CEF19, Epstein-Barr Virus latent NA-3A 458-466
Reviews
Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *